Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate‐to‐severe chronic kidney disease (AWARD‐7). Issue 6 (29th March 2019)
- Record Type:
- Journal Article
- Title:
- Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate‐to‐severe chronic kidney disease (AWARD‐7). Issue 6 (29th March 2019)
- Main Title:
- Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate‐to‐severe chronic kidney disease (AWARD‐7)
- Authors:
- Tuttle, Katherine R.
Lakshmanan, Mark C.
Rayner, Brian
Zimmermann, Alan G.
Woodward, Brad
Botros, Fady T. - Abstract:
- Abstract : In patients with type 2 dibetes and moderate‐to‐severe chronic kidney disease, dulaglutide treatment led to body weight (BW) loss and lesser eGFR decline compared to insulin glargine. As BW may affect muscle mass, creatinine‐based eGFR can be altered independently of kidney function. Cystatin C‐based eGFR is not affected by muscle mass. The objective of this post‐hoc analysis was to determine whether the lesser eGFR decline with dulaglutide was related to BW loss. Baseline characteristics were similar between treatments ([mean ± SD] age, 64.6 ± 8.6 years; women, 48%; BW, 89.1 ± 17.7 kg; eGFR [CKD‐EPI‐cystatin C] 38 ± 14 mL/min/1.73m 2 ). BW decreased with dulaglutide 1.5 and 0.75 mg and increased with insulin glargine ([LSM change (SE)], −2.66 [0.47] kg and −1.71 [0.45] vs 1.57 [0.43] kg; P < 0.001). Changes in eGFR were not significant with dulaglutide 1.5 and 0.75 mg, but eGFR significantly decreased with insulin glargine (eGFR‐CKD‐EPI‐cystatin C [LSM change (95%CI)], −0.7 [−2.5, 1.0] and −0.7 [−2.4, 1.1] vs −3.3 [−5.1, −1.6] mL/min/1.73 m 2 ; P ≤ 0.037 vs glargine). Changes in BW did not correlate with changes in eGFR‐CKD‐EPI‐cystatin C (r = −0.041; n = 471; P = 0.379) or eGFR‐CKD‐EPI‐creatinine (r = −0.074; n = 473; P = 0.106). In conclusion, the lesser decline in eGFR observed with dulaglutide was not influenced by BW loss.
- Is Part Of:
- Diabetes, obesity & metabolism. Volume 21:Issue 6(2019)
- Journal:
- Diabetes, obesity & metabolism
- Issue:
- Volume 21:Issue 6(2019)
- Issue Display:
- Volume 21, Issue 6 (2019)
- Year:
- 2019
- Volume:
- 21
- Issue:
- 6
- Issue Sort Value:
- 2019-0021-0006-0000
- Page Start:
- 1493
- Page End:
- 1497
- Publication Date:
- 2019-03-29
- Subjects:
- GLP‐1 -- type 2 diabetes
Diabetes -- Periodicals
Obesity -- Periodicals
Metabolism -- Disorders -- Periodicals
Clinical pharmacology -- Periodicals
616.462 - Journal URLs:
- http://www.blackwellpublishing.com/journal.asp?ref=1462-8902&site=1 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1463-1326 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/dom.13668 ↗
- Languages:
- English
- ISSNs:
- 1462-8902
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3579.601970
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 10117.xml